Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-10-09
2007-10-09
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S203100, C424S184100, C424S245100, C424S247100, C424S242100, C424S240100, C424S239100, C424S254100, C424S238100, C424S197110, C424S832000, C514S002600, C530S350000, C530S825000
Reexamination Certificate
active
10089367
ABSTRACT:
Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) orE. coliheat labile toxin (LT). Component (b) acts as a mucosal adjuvant. The acellular pertussis antigen preferably comprises pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) and, optionally, pertactin. The mucosally-delivered combined DTPa formulation is capable of generating a level of protection againstB. pertussisinfection equivalent to that observed by alum-adjuvanted parenteral administration.
REFERENCES:
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5614382 (1997-03-01), Metcalf
patent: 6562352 (2003-05-01), Roberts et al.
patent: 7115730 (2006-10-01), Pizza et al.
patent: 0462534 (1991-12-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 93/21950 (1993-11-01), None
patent: WO 93/24148 (1993-12-01), None
patent: WO 97/02348 (1997-01-01), None
patent: WO 98/18298 (1998-04-01), None
Ann. lg. 79-84, 1991.
Almeida & Alpar, “Nasal Delivery of Vaccines”,J. Drug Targeting 3: 455-467.
Cahill et al., “Immune responses and protection againstBordetella pertussisinfection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles,”Vaccine 13:455-462, 1995.
Cahill et al., “Mice are protected againstBordetella pertussisinfection by intra-nasal immunization with filamentous haemagglutinin,”FEMS Microbiology Letters 107: 211-216, 1993.
Center for Disease Control and Prevention, “Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among InfaNTS AND young Children-recommendations of the Advisory Committee on Immunization Practices (ACIP)”,Morbid. Mortal. Weekly Rep. 46(RR-7): 1-25, 1997.
Del Giudice et al., “Molecular basis of vaccination,”Molecular Aspects of Medicine 19: 1-70, 1998.
Douce et al., “Mutants ofEscherichia coliheat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants,”PNAS USA 92: 1644-1648, 1995.
Fontana et al., “Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit,”Infect. Immun. 63: 2356-2360, 1995.
Gustafsson et al., “A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine,”N.. Engl. J. Med. 334: 349-355, 1996.
Guzman et al., “Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid,”Infect. Immun. 61: 573-579, 1993.
Hauser et al., “Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis,”Dev. Biol. Stand. 95: 251-255, 1998.
Jones et al., “Orally administered microencapsulatedBordetella pertussisfimbriae protect mice fromB. pertussisrespiratory infection,”Infect. Immun. 64: 489-494, 1996.
Mills et al., “A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection againstBordetella pertussis,”Infect. Immun. 66: 94-602, 1998.
Park et al., “The mucosal adjuvanticity of two nontoxic mutants ofEscherichia coliheat-labile enterotoxin varies with immunization routes.”Exp. Mol. Med. 32: 72-78, 2000.
Podda et al., “Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa,”Vaccine 9: 741-745, 1991.
Rappuoli et al., “Towards third-generation whooping cough vaccines”,Trends in biotechnology 9: 232-238, 1991.
Rapuoli, “Rational design of vaccines,”Nature Medicine 3: 374-376, 1997.
Ryan et al., “The adjuvant action of mutants of the heat labile toxin ofE. colifor a nasally delivered acellular pertussis vaccine,”Immunology Letters 69: 59, 1999.
Ryan et al., “Mutants ofEscherichia coliheat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells,”Infection and Immunity 67: 6270-6280, 1999.
Shahin et al., “Mucosal immunization with filamentous hemagglutinin protects againstBordetella pertussisrespiratory infection,”Infect. Immun. 60: 1482-1488, 1992.
Shahin et al., “Adjuvanticity and protective immunity elicited byBordetella pertussisantigens encapsulated in poly(DL-lactide-co-glycolide) microspheres,”Infect. Immun. 63: 1195-1200, 1995.
Walker, “New strategies for using mucosal vaccination to achieve more effective immunization,”Vaccine 12: 387-400, 1994.
Pizza Mariagrazia
Rappuoli Rino
Devi S.
Lee Helen
Novartis Vaccines and Diagnostics SRL
Robins Roberta L.
LandOfFree
Mucosal DTPa vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mucosal DTPa vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mucosal DTPa vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3888289